ClinicalTrials.gg
RecruitingNCT07947329Updated Nov 18, 2026

Treatments for Menstrual-Related Epilepsy

A Phase 3 interventional study of Clobazam 10 MG Oral Tablet and Acetazolamide 250Mg Tab in Catamenial Epilepsy and Treatment, sponsored by Mazandaran University of Medical Sciences. Recruiting at 1 site in Iran. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Mazandaran University of Medical Sciences · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Mar 2025, registered Nov 2026).
  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Female
01

Study summary

The goal of this randomized clinical trial is to evaluate and compare the efficacy and tolerability of intermittent add-on therapy in adult women of childbearing potential (aged 18-45 years) diagnosed with catamenial epilepsy (C1 perimenstrual pattern).

Read the detailed description

The main questions it aims to answer are:

Does intermittent treatment with clobazam, acetazolamide, or a temporary 25% dose escalation of baseline antiseizure medications (ASMs) significantly reduce seizure frequency during the perimenstrual phase (days -3 to +3) after three consecutive menstrual cycles? What is the comparative tolerability and treatment withdrawal rate due to adverse effects among the three treatment strategies?

Researchers will compare three parallel active intervention arms:

Intermittent oral clobazam (10 mg every 12 hours) on days -5 to +5 of the menstrual cycle.

Intermittent oral acetazolamide (250 mg every 12 hours) on days -5 to +5 of the menstrual cycle.

A 25% dose increase of one of the baseline maintenance ASMs on days -5 to +5 of the menstrual cycle to determine which strategy provides superior seizure control (measured by the proportion of responders achieving ≥50% seizure reduction) with optimal tolerability and minimal adverse events.

Participants will:

Record seizure type and daily frequency in a diary across three baseline consecutive menstrual cycles to confirm C1 catamenial exacerbation prior to randomization.

Take their allocated intermittent study medication (clobazam, acetazolamide, or a 25% increased dose of baseline ASM) every 12 hours from day -5 to day +5 of each menstrual cycle for three consecutive cycles, while continuing their baseline ASMs unchanged.

Maintain a prospective daily seizure log specifically documenting seizure frequency during the perimenstrual window (days -3 to +3).

Attend monthly follow-up visits with a neurologist to report seizure frequency, treatment adherence, and any emergent adverse effects.

02

Conditions studied

  • Catamenial Epilepsy
  • Treatment

Browse trials for

03

In context

Epilepsy

1,850 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

This study's planned enrollment of 90 is above the median of 50 across 1,240 interventional studies indexed under Epilepsy.

Browse Epilepsy studies →

Lead sponsor

Mazandaran University of Medical Sciences is the lead sponsor of 23 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Diagnosis of C1 pattern catamenial epilepsy Regular menstrual cycles

Exclusion criteria

Exclusion Criteria:

History of porphyria History of nephrolithiasis History of renal and hepatic disease History of lung disease Alcohol or drug abuse Use of , sex hormone analogues, or sex hormone derivatives Pregnancy and breastfeeding Benzodiazepine use History of reactions to benzodiazepines or sulfonamides Change in the dose, type, or regimen of antiseizure medication(s) within one month prior to enrollment and during the study

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Clobazam

    One clobazam 10 mg tablet every 12 hours for 3 months on days -5 to +5 of the menstrual cycle.

    Drug: Clobazam 10 MG Oral Tablet

  • Active comparator
    Acetazolamide

    One acetazolamide 250 mg tablet every 12 hours for 3 months on days -5 to +5 of the menstrual cycle.

    Drug: Acetazolamide 250Mg Tab

  • Active comparator
    A 25% increase in the dose of the baseline antiseizure medication

    A 25% increase in the dose of the baseline antiseizure medication for 3 months on days -5 to +5 of the menstrual cycle. If the patient is on polytherapy, the dose of one of the administered antiseizure medications that does not exceed the therapeutic range with a 25% increase will be escalated.

    Drug: Antiepileptic

Interventions

  • DrugClobazam 10 MG Oral Tablet

    clobazam 10 mg tablet every 12 hours

  • Acetazolamide 250Mg Tab every 12 hours

  • DrugAntiepileptic

    A 25% increase in the dose of the baseline antiseizure medication

06

What researchers measure

Primary outcomes

  1. Treatment efficacy in reducing perimenstrual seizure frequency

    responder rate is recorded throughout the study as \>50% seizure reduction (significant improvement), \<50% reduction (partial improvement), or no change (no improvement)

    Time frame: at the end of month 3

Secondary outcomes

  1. Treatment withdrawal rate

    Drug withdrawal due to adverse drug effects or lack of efficacy

    Time frame: at the end of month 3

07

Study locations

1 of 1 sites recruiting
  • Mazandaran University of Medical Sciences
    Sari, Mazandaran, Iran
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Nov 2026, 20 months after the start.

Of 86 phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 69. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartActual
Mar 21, 2025
Primary completionEst.
Nov 21, 2026
CompletionEst.
Jan 21, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07947329
Lead sponsor
Mazandaran University of Medical Sciences
Responsible party
Nasim Tabrizi (Associate professor of neurology, Mazandaran University of Medical Sciences) — Principal investigator
First posted
Nov 18, 2026
Start date
Mar 21, 2025
Primary completion
Nov 21, 2026 (estimated)
Completion
Jan 21, 2027 (estimated)
Last update
Nov 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetazolamide

Start the discussion